Scientists just found a way to trick aggressive prostate cancer cells back into a form that treatment can actually kill.
Quick Take
- Researchers combined two existing drug types to reverse how treatment-resistant prostate cancer cells disguise themselves.
- The combo sharply slowed tumor growth in preclinical lab and mouse experiments.
- The trick targets a process called lineage plasticity, where cancer cells change identity to dodge therapy.
- The findings come from a peer-reviewed study published in JCI Insight, with results still confined to lab models, not patients yet.
How Prostate Cancer Learns to Hide From Treatment
Prostate cancer usually depends on the hormone testosterone to grow. Standard treatments cut off that fuel supply. But some tumors fight back by changing their own identity, a process scientists call lineage plasticity. The cancer cells stop acting like typical prostate cells and start behaving like a different, tougher cell type that no longer needs testosterone to survive.
This shape-shifting trick shows up in a meaningful slice of advanced cases. Roughly a quarter to a third of castration-resistant prostate tumors develop this identity switch, according to researchers studying the pattern. Once cancer cells pull off this transformation, hormone therapy stops working, and doctors run out of easy options. That reality has pushed researchers to hunt for a way to block the switch itself.
Two Drugs, One Combined Attack on Cancer’s Disguise
The new study, published in JCI Insight, tested a combination approach. Researchers paired BET bromodomain inhibitors, drugs that block proteins controlling gene activity, with DNMT inhibitors, which interfere with chemical tags on DNA that cells use to lock in new identities. Used alone, each drug type has shown some promise. Together, they hit the problem from two directions at once.
The results stood out. Combining the two drug classes reversed many of the identity changes tumor cells had made and sharply slowed tumor growth in preclinical experiments. The study specifically found the combination worked better than either drug alone against aggressive tumor models marked by loss of the TP53 and RB1 genes, models known for switching into a stem-cell-like or neuroendocrine form that resists standard treatment.
Why This Fits a Larger Pattern in Cancer Research
This discovery does not stand alone. It builds on years of work showing that BET inhibitors can block the pathways cancer cells use to activate alternate identity programs, work led by researchers including Dr. Joshi Alumkal at the University of Michigan Rogel Cancer Center. Separate teams at Fred Hutchinson Cancer Center and other institutions have also been mapping how these identity switches happen at the molecular level.
Scientists describe lineage plasticity as one of the biggest open problems in advanced prostate cancer today. A widely cited review in Clinical Cancer Research called for urgent progress on understanding how these identity shifts occur and how to stop them, noting that few clinical trials currently address the question and that patient outcomes remain poor once a tumor makes the switch. This new drug combination directly answers that call, at least in the lab.
What Happens Next for Patients and Research
The study’s authors, including Michael Haffner, Leigh Ellis, Yuzhuo Wang, Joel Yates, and Joshi Alumkal, worked across multiple cancer centers to build the case for this combination approach. Their work suggests combined BET bromodomain and DNMT inhibition is a promising therapeutic strategy for tumors that have transformed into these hard-to-treat forms.
These results come from cell lines and animal models, not human patients. That is standard early-stage cancer research, and it typically takes years before a lab finding like this reaches clinical trials. Still, for a disease where roughly a third of resistant cases involve this identity-switching trick, a drug combination that can reverse it in the lab marks a real step toward new options for men who have run out of them.
Sources:
sciencedaily.com, fredhutch.org, mskcc.org, conservancy.umn.edu, michiganmedicine.org, insight.jci.org, pubmed.ncbi.nlm.nih.gov
